NIDA Funding Strategy for Fiscal Year 2014

This is Archived Content. This content is available for historical purposes only. It may not reflect the current state of science or language from the National Institute on Drug Abuse (NIDA). View current information on nida.nih.gov.

Mission

NIDA's mission is to lead the Nation in bringing the power of science to bear on drug abuse and addiction. 

This charge has two critical components.  The first is the strategic support and conduct of research across a broad range of disciplines.  The second is ensuring the rapid and effective dissemination and use of the results of that research to significantly improve prevention, treatment and policy as it relates to drug abuse and addiction. 

Funding Strategy

Funding decisions will be based primarily on programmatic priority of the Institute and scientific merit of the application.  NIDA continues to give additional consideration to first-time R01 investigators and Early Stage Investigators (by NIH definition).

Information regarding FY 2014 NIH Extramural Financial Operations can be found at:

The National Institute on Drug Abuse (NIDA) has established the following funding policy for FY 2014.

Competing Awards

NIDA may reduce competing awards from IRG recommended levels in order to increase the number of awards issued. 

  • New and competing awards will be funded at an average cost of 1% over FY 13 levels.
  • *In general renewal grants should not increase by more than 10% over the prior year’s award.

Non-Competing Continuations Awards

Consistent with overall NIH policy:

  • Non-competing continuation awards will be funded at 100% of committed levels.
  • FY 2014 awards that have already been issued at 90% of committed level will be revised to adjust the award level.
  • Future year commitments will remain unchanged.
  • Ruth L. Kirschstein National Research Service Awards (NRSA) (Fs and Ts) will be funded with stipend increases (i.e., 2% for Predocs and 4% for Postdocs).

NIDA will continue to support the: